Joint Pain, Mobility, and Blushwood Berry Extract: What Users Are Saying in 2026
A growing number of blushwood berry extract users are reporting improvements in joint pain and mobility, adding to an evolving body of consumer-reported outcomes.
Soil Mycorrhizae and Fontainea picrosperma: The Underground Network Behind Blushwood Berry Chemistry
The mycorrhizal fungi associated with Fontainea picrosperma roots may play an underappreciated role in the biosynthesis and concentration of tigilanol tiglate in blushwood fruit.
Wound Healing After Intratumoral EBC-46 Injection: What Phase I Data Reveals
Phase I trial data shows that wound healing after intratumoral EBC-46 injection follows a predictable pattern, with most treated sites closing within four to six weeks.
Neutrophil Recruitment and Tumour Clearance: The Innate Immune Response to EBC-46
EBC-46 triggers rapid neutrophil infiltration at the injection site, creating a localised inflammatory response that accelerates tumour clearance within hours.
FDA Botanical Drug Pathway: How IND Applications Shape the Future of EBC-46
The FDA botanical drug pathway offers a unique regulatory route for plant-derived compounds like EBC-46, with specific IND requirements that differ from synthetic drugs.
Warts, Cysts, and Benign Growths: What Blushwood Berry Extract Users Self-Report as Targets
Blushwood berry extract users increasingly report applying it to warts, sebaceous cysts, and skin tags. Here's what those reports show, and where the science is plausible versus speculative.
Biosynthesis of Tigilanol Tiglate: The Enzymatic Pathway Inside Fontainea picrosperma
The blushwood tree doesn't just produce tigilanol tiglate — it manufactures it through a complex series of enzymatic steps. Here's what science knows about that biosynthetic pathway.
Complete Response vs Partial Response in EBC-46 Trials: How Clinical Researchers Define and Measure Success
How do EBC-46 trial investigators decide whether a treatment worked? The answer lies in RECIST 1.1 criteria and the specific challenges of measuring response in intratumoral therapy.
NF-κB Suppression and EBC-46: How PKC Activation Disrupts Tumour Survival Signalling
EBC-46's activation of protein kinase C does more than disrupt tumour vasculature — it may also suppress NF-κB, one of cancer's most critical survival signalling pathways.
Accelerated Approval and EBC-46: Surrogate Endpoints, Biomarkers, and the Path to Conditional Clearance
The FDA's Accelerated Approval pathway could allow tigilanol tiglate to reach patients before full Phase III data is available — here's how surrogate endpoints make that possible.
Diacylglycerol Mimicry: Why EBC-46 Binds PKC with Exceptional Selectivity
EBC-46 mimics the natural lipid messenger diacylglycerol to activate specific PKC isoforms — a molecular trick that explains its targeted anti-tumour effects.
Compassionate Use Pathways for Tigilanol Tiglate: How Patients May Access EBC-46 Before Full Approval
Compassionate use and expanded access programmes could allow terminal patients to receive tigilanol tiglate before regulatory approval is finalised.